Pascal Sirvent

About Pascal Sirvent

Pascal Sirvent holds a strategic position at Valbiotis at the intersection of science, innovation and corporate governance: he is the company’s Chief Scientific Officer (CSO), Scientific Director and a member of the Management Board. In this capacity, he plays a central role in defining and executing the group’s R&D strategy. Valbiotis focuses on developing innovative nutritional solutions for the prevention of cardio-metabolic disorders and for nutritional support. Within the organization, Sirvent oversees Discovery, preclinical and translational research, as well as the company’s two R&D centers in La Rochelle and Riom. His academic and scientific background underpins his expertise. Sirvent has more than 15 years of research experience and is widely recognized for his specialization in metabolic diseases. He served as a Lecturer at the University of Clermont Auvergne from 2008 to 2018 and has led the university’s functional assessment technical platform since 2010. During that period, he initiated several international scientific collaborations with Vanderbilt University, the Maine Medical Center Research Institute and the University of Texas, focusing on the pathophysiology of type 2 diabetes. He earned a PhD in Biological and Biochemical Health Sciences in 2005 and later obtained the French HDR qualification in 2016, which authorizes the supervision of doctoral research. Sirvent has been closely involved with Valbiotis since its creation in 2014. He first contributed through the Scientific Committee, where he was responsible for collaborative projects between the University of Clermont Auvergne and the company. In 2017, he joined Valbiotis as Head of Discovery and Preclinical Research, before later taking on broader scientific leadership responsibilities. This career progression reflects both his scientific credibility and his ability to translate research into differentiated development assets. Valbiotis also identifies him as co-inventor of several key technologies used in the company’s product development. In a listed company such as Valbiotis, Sirvent’s profile is particularly valuable because it helps ensure scientific rigor, strengthens academic partnerships and supports the development of clinically backed solutions. His contribution is aligned with long-term value creation through the industrialization of research, the reinforcement of innovation capabilities and the expansion of the company’s product portfolio.